EP1017387A4 - Vitronectin receptor antagonist - Google Patents

Vitronectin receptor antagonist

Info

Publication number
EP1017387A4
EP1017387A4 EP98949454A EP98949454A EP1017387A4 EP 1017387 A4 EP1017387 A4 EP 1017387A4 EP 98949454 A EP98949454 A EP 98949454A EP 98949454 A EP98949454 A EP 98949454A EP 1017387 A4 EP1017387 A4 EP 1017387A4
Authority
EP
European Patent Office
Prior art keywords
receptor antagonist
vitronectin receptor
vitronectin
antagonist
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98949454A
Other languages
German (de)
French (fr)
Other versions
EP1017387A1 (en
Inventor
Dirk Heerding
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1017387A1 publication Critical patent/EP1017387A1/en
Publication of EP1017387A4 publication Critical patent/EP1017387A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
EP98949454A 1997-09-24 1998-09-24 Vitronectin receptor antagonist Withdrawn EP1017387A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5983297P 1997-09-24 1997-09-24
US59832P 1997-09-24
PCT/US1998/019949 WO1999015170A1 (en) 1997-09-24 1998-09-24 Vitronectin receptor antagonist

Publications (2)

Publication Number Publication Date
EP1017387A1 EP1017387A1 (en) 2000-07-12
EP1017387A4 true EP1017387A4 (en) 2004-08-18

Family

ID=22025570

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98949454A Withdrawn EP1017387A4 (en) 1997-09-24 1998-09-24 Vitronectin receptor antagonist

Country Status (13)

Country Link
EP (1) EP1017387A4 (en)
JP (1) JP2002528380A (en)
KR (1) KR20010024247A (en)
CN (1) CN1273529A (en)
AU (1) AU9577498A (en)
BR (1) BR9813208A (en)
CA (1) CA2303846A1 (en)
HU (1) HUP0003949A2 (en)
IL (1) IL135189A0 (en)
NO (1) NO20001514D0 (en)
PL (1) PL339413A1 (en)
TR (1) TR200000792T2 (en)
WO (1) WO1999015170A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU747503B2 (en) 1999-02-03 2002-05-16 Merck & Co., Inc. Benzazepine derivatives as alpha-V integrin receptor antagonists
US6514964B1 (en) * 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
JP2004521079A (en) * 2000-08-29 2004-07-15 ファルマシア・コーポレーション Compounds containing bicyclic ring systems useful as alpha vbeta3 antagonists
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
IL154496A0 (en) * 2000-08-30 2003-09-17 Pharmacia Corp GEM-SUBSTITUTED alpha v beta3 INTEGRIN ANTAGONISTS
CZ20033119A3 (en) 2001-04-24 2005-01-12 Merck Patent Gmbh Combination therapy using anti-angiogenic agents and TNF alpha
KR20100054884A (en) 2001-10-22 2010-05-25 더 스크립스 리서치 인스티튜트 Antibody targeting compounds
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
EA016817B1 (en) 2006-01-18 2012-07-30 Мерк Патент Гмбх Specific therapy using integrin ligands for treating cancer
KR20090108713A (en) 2007-01-18 2009-10-16 메르크 파텐트 게엠베하 Specific therapy and medicament using integrin ligands for treating cancer
JP5359879B2 (en) * 2007-11-16 2013-12-04 宇部興産株式会社 Benzazepinone compounds
EP2257538B1 (en) * 2008-03-06 2016-04-27 GlaxoSmithKline LLC Process for the preparation of benzodiazepine derivatives
US8518927B2 (en) 2009-02-10 2013-08-27 The Scripps Research Institute Chemically programmed vaccination
WO2010113958A1 (en) 2009-03-30 2010-10-07 宇部興産株式会社 Pharmaceutical composition for treatment or prevention of ophthalmic diseases
JP5572996B2 (en) * 2009-05-15 2014-08-20 宇部興産株式会社 Medicine containing benzazepinone compound as active ingredient
KR20120104491A (en) 2009-05-25 2012-09-21 메르크 파텐트 게엠베하 Continuous administration of cilengitide in cancer treatments
CN103864765B (en) * 2014-03-05 2016-02-10 天津药物研究院 Benzazepine analog derivative containing five-membered ring, Preparation Method And The Use
RU2016146826A (en) 2014-05-30 2018-07-04 Пфайзер Инк. CARBONITRIL DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000574A1 (en) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60311C2 (en) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Vitronectin receptor antagonists
EP0946180A4 (en) * 1996-10-07 2003-07-23 Smithkline Beecham Corp Method for stimulating bone formation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000574A1 (en) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists

Also Published As

Publication number Publication date
CN1273529A (en) 2000-11-15
EP1017387A1 (en) 2000-07-12
CA2303846A1 (en) 1999-04-01
JP2002528380A (en) 2002-09-03
HUP0003949A2 (en) 2001-10-28
KR20010024247A (en) 2001-03-26
TR200000792T2 (en) 2000-09-21
NO20001514L (en) 2000-03-23
WO1999015170A1 (en) 1999-04-01
PL339413A1 (en) 2000-12-18
NO20001514D0 (en) 2000-03-23
AU9577498A (en) 1999-04-12
BR9813208A (en) 2000-08-22
IL135189A0 (en) 2001-05-20

Similar Documents

Publication Publication Date Title
EP1000031A4 (en) Vitronectin receptor antagonist
CY2576B1 (en) Vitronectin receptor antagonists
EP0767792A4 (en) Vitronectin receptor antagonists
ZA955391B (en) Vitronectin receptor antagonists
IL130760A0 (en) Vitronectin receptor antagonists
IL142958A0 (en) Vitronectin receptor antagonist pharmaceuticals
HUP9900754A3 (en) Vitronectin receptor antagonists
EP0895475A4 (en) Vitronectin receptor antagonists
IL135189A0 (en) Vitronectin receptor antagonist
IL135188A0 (en) Vitronectin receptor antagonist
PL342881A1 (en) Vitronectin receptor antagonists
IL135028A0 (en) Vitronectin receptor antagonists
EG24025A (en) Vitronectin receptor antagonist
PL346157A1 (en) Vitronectin receptor antagonists
ZA988562B (en) Vitronectin receptor antagonists
GB9810882D0 (en) Vitronectin receptor antagonists
GB9810892D0 (en) Vitronectin receptor antagonists
GB9810182D0 (en) Vitronectin receptor antagonists
GB9807384D0 (en) Vitronectin receptor antagonists
GB9807382D0 (en) Vitronectin receptor antagonists
GB9811295D0 (en) Vitronectin receptor antagonists
GB9812686D0 (en) Vitronectin receptor antagonists
GB9815803D0 (en) Vitronectin receptor antagonists
GB9822331D0 (en) Vitronectin receptor antagonists
SI0957917T1 (en) Vitronectin receptor antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000328

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 20000328

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HEERDING, DIRK, SMITHKLINE BEECHAM PHARMACEUTICALS

A4 Supplementary search report drawn up and despatched

Effective date: 20040706

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 3/14 B

Ipc: 7C 07D 413/12 B

Ipc: 7C 07D 403/12 B

Ipc: 7C 07D 401/14 B

Ipc: 7C 07D 401/12 B

Ipc: 7A 61K 31/495 B

Ipc: 7A 61K 31/445 B

Ipc: 7A 61K 31/415 B

Ipc: 7A 61K 31/55 B

Ipc: 7A 61K 31/52 B

Ipc: 7A 61K 31/47 B

Ipc: 7A 61K 31/44 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20041002

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1030743

Country of ref document: HK